{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T21:08:21Z","timestamp":1769288901187,"version":"3.49.0"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[1996,5,1]],"date-time":"1996-05-01T00:00:00Z","timestamp":830908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1996,5]]},"abstract":"<jats:p>The new triazole derivative SCH 56592 has been tested in a National Committee for Clinical Laboratory Standards-adapted in vitro susceptibility test, and its activity against 12 isolates of Blastomyces dermatitidis yeast-like forms has been compared with those of amphotericin B, itraconazole, and fluconazole. SCH 56592 was the most active of the four compounds, with an MIC at which 90% of the isolates are inhibited of 0.06 microgram\/ml and a minimal fungicidal concentration at which 90% of the isolates are inhibited of 4 micrograms\/ml. The results of the treatment of mice infected with B. dermatitidis with three different doses of SCH 56592 (25, 5, or 1 mg\/kg of body weight), amphotericin B (1 mg\/kg), or itraconazole (150 mg\/kg) confirmed the potent activity of SCH 56592. Survival was prolonged at each dose of SCH 56592, and sterilization of the lungs occurred in the high-dose group but not in the groups treated with itraconazole or fluconazole. SCH 56592 is a promising new azole antifungal drug that should be studied in humans with blastomycosis.<\/jats:p>","DOI":"10.1128\/aac.40.5.1314","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:25:20Z","timestamp":1539044720000},"page":"1314-1316","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":82,"title":["In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis"],"prefix":"10.1128","volume":"40","author":[{"given":"A M","family":"Sugar","sequence":"first","affiliation":[{"name":"Evans Memorial Department of Clinical Research, Boston University Medical Center Hospital, MA 02118, USA. asugar@med-med1.bu.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X P","family":"Liu","sequence":"additional","affiliation":[{"name":"Evans Memorial Department of Clinical Research, Boston University Medical Center Hospital, MA 02118, USA. asugar@med-med1.bu.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.40.5.1314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.40.5.1314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:10:12Z","timestamp":1645474212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.40.5.1314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,5]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,5]]}},"alternative-id":["10.1128\/AAC.40.5.1314"],"URL":"https:\/\/doi.org\/10.1128\/aac.40.5.1314","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,5]]},"assertion":[{"value":"1996-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}